NCT04956042 - Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 27, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

Refractory Acute Myeloid LeukemiaRecurrent Acute Myeloid Leukemia

Interventions

DRUG

Fosciclopirox

Fosciclopirox, 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle

DRUG

Fosciclopirox + Cytarabine

"Fosciclopirox - 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle~Cytarabine - 1g/m2 once daily on D1-D5 of each 21-day treatment cycle"

Trial Locations (2)

21287

John Hopkins School of Medicine, Baltimore

66160

University of Kansas Medical Center, Kansas City